Nektar Therapeutics NKTR Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $10.86M+3.8% | $21.81M-25.3% | $11.79M-51.1% | $11.18M-52.4% | $10.46M-51.7% | ||
| —— | $21.81M+2.9% | $11.79M-40.1% | $11.18M-18.7% | $10.46M-20.2% | ||
| $35.68M+17.1% | $29.71M+3.4% | $27.25M-22.2% | $29.89M+0.5% | $30.48M+11.2% | ||
| $13.44M-44.8% | $11.19M-34.7% | $16.07M-15.2% | $17.07M-16.8% | $24.35M+20.8% | ||
| $49.92M-9.2% | $49.47M+234% | $43.46M-25.7% | $47.41M-35.3% | $55M-3.6% | ||
| -$39.05M+12.3% | -$27.67M— | -$31.67M+7.8% | -$36.23M+27.2% | -$44.54M-25.7% | ||
| -359.6%+66.2pp | -126.9%— | -268.6%-126pp | -324.2%-112pp | -425.8%-262pp | ||
| $4.24M+47.6% | $2.78M-5.6% | $2.82M-18.0% | $1.97M-49.5% | $2.87M-31.9% | ||
| -$4.04M-120% | -$7.04M+4.2% | -$3.35M-23.9% | -$3.17M-24.5% | -$1.83M-30.1% | ||
| -$1.75M+60.8% | -$1.35M— | -$534K— | -$2.39M— | -$4.46M— | ||
| -$43.09M+7.1% | -$34.7M— | -$35.02M+5.5% | -$39.4M+24.7% | -$46.37M-25.9% | ||
| $64K+23.1% | —— | -$33K-467% | -$188K-509% | $52K+249% | ||
| -$44.9M+11.7% | -$36.08M— | -$35.52M+4.1% | -$41.59M+20.6% | -$50.88M-38.3% | ||
| -413.4%+73.0pp | -165.4%-165pp | -301.3%-148pp | -372.2%-149pp | -486.4%-316pp | ||
| -$1.82+49.7% | -$1.59+23.2% | -$1.87+29.7% | -$2.95+21.5% | -$3.62-1,805% | ||
| -$1.82+49.7% | -$1.59+23.2% | -$1.87+29.7% | -$2.95+21.5% | -$3.62-1,805% | ||
| 24.7M+75.9% | 16.9M+23.0% | 18.9M+35.8% | 14.1M+1.2% | 14.1M-92.8% | ||
| 24.7M+75.9% | 16.9M+23.0% | 18.9M+35.8% | 14.1M+1.2% | 14.1M-92.8% | ||
| —— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| $7.94M+59.7% | $9.77M-3.8% | $6.05M+0.4% | $5.39M-15.8% | $4.97M-10.1% | ||
| -$43.15M+7.0% | -$34.73M— | -$34.99M+5.6% | -$39.21M+25.1% | -$46.42M-26.1% | ||
| -$336K-226% | —— | -$121K-0.8% | $260K+822% | $266K+369% | ||
| $796K+371% | $8.58M+531% | $140K+204% | $447K-96.6% | $169K-82.7% | ||
| $10.86M+3.8% | $21.81M-25.3% | $11.79M-51.1% | $11.18M-52.4% | $10.46M-51.7% | ||
| -$39.05M+12.3% | -$27.67M— | -$31.67M+7.8% | -$36.23M+27.2% | -$44.54M-25.7% | ||
| -$38.9M+11.8% | -$27.48M-8,376% | -$31.48M+5.6% | -$36.02M+25.5% | -$44.11M-30.4% | ||
| -$38.9M+11.8% | -$27.48M-8,376% | -$31.48M+5.6% | -$36.02M+25.5% | -$44.11M-30.4% | ||
| -358.2%+63.5pp | -126%-127pp | -267%-129pp | -322.3%-117pp | -421.7%-265pp | ||
| -$39.05M+12.3% | -$27.67M— | -$31.67M+7.8% | -$36.23M+27.2% | -$44.54M-25.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Nektar Therapeutics's profit margins?
- Gross margin is 100.0% and operating margin is -242.0%, with a -284.2% net margin.
- Where does Nektar Therapeutics's income statement data come from?
- Every line is extracted from Nektar Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.